spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck to Provide Provantage® End-to-End Services to Acticor Biotech SAS

Merck Serono

Leading science and technology company announces that it will provide its Provantage services to Acticor Biotech SAS

  • Accelerates development and manufacture of Acticor's antibody fragment that treats ischemic stroke
Darmstadt, Germany, December 5, 2016 - Merck, a leading science and technology company, today announced that it will provide its Provantage® End-to-End services to Acticor Biotech SAS for accelerated development and manufacturing of Acticor's antibody fragment used for the primary treatment of ischemic stroke.

Merck's Provantage® End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate progress of molecules into the clinic and toward commercialization.

"Our Provantage® End-to-End solution will provide Acticor with a fast and flexible approach to development and clinical-scale manufacturing," said Udit Batra, member of the Merck Executive Board and CEO, Life Science. "We look forward to executing full process development for the antibody fragment, which will help accelerate this important new molecule through the pipeline to patients in need."

The turnkey package includes process development, cGMP clinical manufacturing, quality and regulatory support, training, commercial facilities design, engineering and build-up as well as production equipment supply and process technical transfer activities.

"Stroke is the third leading cause of death in the world and the first cause of disabilities in adults," said Gilles Avenard, CEO, Acticor Biotech. "Motivated by these statistics, we are developing innovative therapeutic strategies for safe and effective emergency treatment of the acute phase of ischemic strokes. Through our collaboration with Merck, we now have access to a comprehensive set of development and manufacturing services that will help us deliver on our mission."

Merck's Provantage® End-to-End solution delivers important benefits and addresses key challenges for biopharmaceutical companies at all life cycle stages in any geography, including established biopharmaceutical companies decentralizing manufacturing that must rapidly and efficiently establish local production capabilities. With an end-to-end approach, Merck can facilitate and accelerate transfer of an entire process to a new location. Early-stage companies with limited manufacturing capabilities, resources and infrastructure benefit from a partner with best-in-class unit operations and the support and expertise to develop processes and production facilities.
phone +44 (0) 20 8818 7200
email http://www.merckserono.co.uk/en/index.html
email Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Pearls of the Aegean are now at the dining tables of Kuwait by Turkish Cargo


More info >>


White Papers

Stripping the confusion out of PVC curtains... and a new seat range.

Teknomek Ltd

With the ever-growing trend towards modularisation of clean rooms and laboratories; Teknomek have responded with a new range of PVC strip curtains, suitable for use in environments where maintaining clean airflow is critical. This new PVC curtain range includes specialist perforated and electrostatic discharge alternatives to the standard options of clear and polar (-25oC) versions.
More info >>

Industry Events

Outsourcing in Clinical Trials New England

6-7 September 2017, Boston

Registration is now open for the flagship conference, OCT New England which will return to Boston this September. Following the tremendous success of the 2016 event, the OCT team have been busy putting together the most content driven, high quality agenda to date. The speaker line-up is the best so far, with senior professionals from across the field currently finalizing their interactive presentations and sessions.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement